TerminatedPhase 2NCT03505710
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daiichi Sankyo
- Principal Investigator
- Global Team LeaderDaiichi Sankyo
- Intervention
- Trastuzumab deruxtecan(drug)
- Enrollment
- 181 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2024
Study locations (21)
- University of California San Diego (UCSD), La Jolla, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Washington University School of Medicine at St. Louis, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University of Washington, Seattle, Washington, United States
- Centre Leon Berard, Lyon, Rhne, France
- Hôpital Nord - CHU Marseille, Marseille, France
- CHU Larrey, Toulouse, France
- Hôpital Larrey, CHU-Toulouse, Toulouse, France
- Institut Gustave Roussy, Villejuif, Île-de-France Region, France
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
- +6 more locations on ClinicalTrials.gov
Collaborators
Daiichi Sankyo Co., Ltd. · AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03505710 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07185997Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.